Company intelligence
PILA PHARMA
We are a #TRPV1 focused company developing oral treatments for Type-2 #Diabetes & #Erythromelalgia
About PILA PHARMA
PILA PHARMA is a publicly held clinical stage pharmaceutical company based in Malmö, Sweden. PILA PHARMA is developing a novel type of oral anti-diabetic agent: a TRPV1 antagonist for the treatment of diabetes.
Verified activity
Signals from PILA PHARMA
9 published signals
Research & Knowledge
PILA PHARMA released its last report and regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist as a potential first-in-class candidate.
Reported by PILA PHARMA
Research & Knowledge
PILA PHARMA announced the regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist, a potential first-in-class candidate.
Reported by PILA PHARMA
Legal & Regulatory
PILA PHARMA received regulatory approval for its next 3-month study in people with obesity using an oral small-molecule TRPV1 antagonist.
Reported by PILA PHARMA
Capital & Finance
PILA PHARMA reported on its IPO prospectus and regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist as a potential first-in-class candidate.
Reported by PILA PHARMA
Research & Knowledge
PILA PHARMA published a regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist as a potential first-in-class candidate.
Reported by PILA PHARMA
Research & Knowledge
PILA PHARMA received regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist as a potential first-in-class candidate.
Reported by PILA PHARMA
Research & Knowledge
PILA PHARMA released its regulatory approval for a new longer clinical trial in people with obesity using an oral TRPV1 antagonist, a potential first-in-class candidate.
Reported by PILA PHARMA
Capital & Finance
PILA PHARMA released its H1 financial report last week, with a trip to Stockholm to attend the release.
Reported by Gustav Hanghøj Gram
Presence & Recognition
PILA PHARMA hosted a live review of H1 and commented on regulatory approval for a new longer clinical trial to explore higher doses with Infront Direkt Studios
Reported by PILA PHARMA